These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15522446)

  • 21. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.
    Hartman AL; Bird BH; Towner JS; Antoniadou ZA; Zaki SR; Nichol ST
    J Virol; 2008 Mar; 82(6):2699-704. PubMed ID: 18199658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein.
    Feldmann H; Nichol ST; Klenk HD; Peters CJ; Sanchez A
    Virology; 1994 Mar; 199(2):469-73. PubMed ID: 8122375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis.
    Fang J; Pietzsch C; Ramanathan P; Santos RI; Ilinykh PA; Garcia-Blanco MA; Bukreyev A; Bradrick SS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus.
    Murray JL; Mavrakis M; McDonald NJ; Yilla M; Sheng J; Bellini WJ; Zhao L; Le Doux JM; Shaw MW; Luo CC; Lippincott-Schwartz J; Sanchez A; Rubin DH; Hodge TW
    J Virol; 2005 Sep; 79(18):11742-51. PubMed ID: 16140752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Insight into Nucleoprotein Conformation Change Chaperoned by VP35 Peptide in Marburg Virus.
    Liu B; Dong S; Li G; Wang W; Liu X; Wang Y; Yang C; Rao Z; Guo Y
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ebola virus defective interfering particles and persistent infection.
    Calain P; Monroe MC; Nichol ST
    Virology; 1999 Sep; 262(1):114-28. PubMed ID: 10489346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.
    Towner JS; Paragas J; Dover JE; Gupta M; Goldsmith CS; Huggins JW; Nichol ST
    Virology; 2005 Feb; 332(1):20-7. PubMed ID: 15661137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic Phosphorylation of VP30 Is Essential for Ebola Virus Life Cycle.
    Biedenkopf N; Lier C; Becker S
    J Virol; 2016 May; 90(10):4914-4925. PubMed ID: 26937028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional mapping of the nucleoprotein of Ebola virus.
    Watanabe S; Noda T; Kawaoka Y
    J Virol; 2006 Apr; 80(8):3743-51. PubMed ID: 16571791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of subtype Zaire Ebola virus in Gabon.
    Volchkov V; Volchkova V; Eckel C; Klenk HD; Bouloy M; LeGuenno B; Feldmann H
    Virology; 1997 May; 232(1):139-44. PubMed ID: 9185597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.
    Prins KC; Binning JM; Shabman RS; Leung DW; Amarasinghe GK; Basler CF
    J Virol; 2010 Oct; 84(20):10581-91. PubMed ID: 20686031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development.
    Witko SE; Kotash CS; Nowak RM; Johnson JE; Boutilier LA; Melville KJ; Heron SG; Clarke DK; Abramovitz AS; Hendry RM; Sidhu MS; Udem SA; Parks CL
    J Virol Methods; 2006 Jul; 135(1):91-101. PubMed ID: 16569439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple phosphorylable sites in the Zaire Ebolavirus nucleoprotein evidenced by high resolution tandem mass spectrometry.
    Peyrol J; Thizon C; Gaillard JC; Marchetti C; Armengaud J; Rollin-Genetet F
    J Virol Methods; 2013 Jan; 187(1):159-65. PubMed ID: 23068963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets.
    Basler CF; Krogan NJ; Leung DW; Amarasinghe GK
    Antiviral Res; 2019 Feb; 162():90-100. PubMed ID: 30550800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Borna disease virus matrix protein is an integral component of the viral ribonucleoprotein complex that does not interfere with polymerase activity.
    Chase G; Mayer D; Hildebrand A; Frank R; Hayashi Y; Tomonaga K; Schwemmle M
    J Virol; 2007 Jan; 81(2):743-9. PubMed ID: 17079312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of filoviruses by electron microscopy.
    Geisbert TW; Jahrling PB
    Virus Res; 1995 Dec; 39(2-3):129-50. PubMed ID: 8837880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics.
    Groseth A; Hoenen T; Alimonti JB; Zielecki F; Ebihara H; Theriault S; Ströher U; Becker S; Feldmann H
    J Infect Dis; 2007 Nov; 196 Suppl 2():S382-9. PubMed ID: 17940974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation.
    Noda T; Kolesnikova L; Becker S; Kawaoka Y
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S878-83. PubMed ID: 21987764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular biology and evolution of filoviruses.
    Feldmann H; Klenk HD; Sanchez A
    Arch Virol Suppl; 1993; 7():81-100. PubMed ID: 8219816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current perspectives on the phylogeny of Filoviridae.
    Barrette RW; Xu L; Rowland JM; McIntosh MT
    Infect Genet Evol; 2011 Oct; 11(7):1514-9. PubMed ID: 21742058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.